With over 30 years of experience in the pharmaceutical and nutraceutical industries, Paul Edalat is a visionary industry disruptor driven by his desire to transform the pharmaceutical industry to better serve patients and consumers.
Edalat discovered his passion for tennis, weightlifting, and overall health and wellness at a young age. Harnessing his firsthand experiences and business acumen to pursue the American dream, Edalat set out to revolutionize the burgeoning fitness and wellness industries.
While Edalat continues to be passionate about athletics and fitness, his priorities shifted following his brother’s Hodgkin’s Lymphoma diagnosis in 2004. Edalat remained by his brother’s side throughout his battle with cancer; however, he sadly passed away two short years after his initial diagnosis. Ever since, Edalat has devoted himself to developing innovative pain management therapies and science-driven solutions that prioritize people over profit in honor of his brother’s lasting legacy.
As the Chairman and CEO of Vivera Pharmaceuticals, Edalat’s mission is to upend an outdated industry to improve the lives and wellbeing of all Americans: regardless of race, socioeconomics, or any other social determinant of health. He is a true believer in the power of future-focused medicine to ensure equitable health opportunities for all. Working with Vivera’s team of scientists, doctors, and advisors, the Company is leading the way with innovative new technologies such as its patented ZICOH drug delivery device and the patented TABMELT sublingual drug delivery system. Most recently, Vivera’s team received a patent for the Company’s MDZone, a self-Contained, portable, Telemedicine Station. MDZone will be a HIPAA compliant, portable telemedicine station that will allow patients to access health care and connect with a medical provider remotely. Together with the team, Edalat leads a whole-patient approach to treatment, focusing on the synergistic roles mental and physical health have together. With the Company’s expansion into medical technologies and neurosciences, Edalat wants to bring a fresh new perspective to how patient care can be achieved.
Edalat continues to grow in his career as a forward-thinking entrepreneur. Most recently, Edalat was vetted and selected as a member of the Forbes Council by a review committee based on the depth and diversity of his professional background in leadership, management, and growth. Edalat was also an honorable nominee of the OBCJ’s 2022 Excellence in Entrepreneur Awards. As Edalat continues to move forward in the pharmaceutical industry, his mission has always been to prioritize patients over profit.
Duis sed odio sit amet nibh vulputate cursus a sit amet mauris. Morbi accums an ipsum velit. Nam nec tellus a odio tincidunt auctor a ornare odio.